Patents by Inventor Melvin C. Rutledge

Melvin C. Rutledge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused cycloheptane and fused azacycloheptane compounds and their methods of use
    Patent number: 6514964
    Abstract: The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as &agr;v&bgr;3, &agr;v&bgr;5, &agr;v&bgr;6 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: February 4, 2003
    Assignee: Amgen Inc.
    Inventors: Zhidong Chen, Celia Dominguez, Ellen Grenzer-Laber, Nianhe Han, Longbing Liu, Ofir A. Moreno, Melvin C. Rutledge, Andrew S. Tasker
  • IL-8 receptor antagonists
    Patent number: 6300325
    Abstract: This invention relates to novel benzo-2-triazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO&agr;, GRO&bgr;, GRO&ggr; and NAP-2 mediated diseases.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: October 9, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine L. Widdowson, Melvin C. Rutledge
  • IL-8 receptor antagonists
    Patent number: 6221889
    Abstract: This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 &agr; or &bgr; receptor and which method comprises administering an effective amount of a compound of Formular (I) or a pharmaceuticlly acceptable salt thereof. In particular the chemokine is IL-8.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: April 24, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Melvin C. Rutledge, Jr., Katherine L. Widdowson